+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anti-Obesity Therapeutics Market by Treatment Type, Drug Type, Route Of Administration, Drug Formulation, End-User, Distribution Channel - Global Forecast to 2030- Product Image
Anti-Obesity Therapeutics Market by Treatment Type, Drug Type, Route Of Administration, Drug Formulation, End-User, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Anti-Obesity Therapeutics Market by Treatment Type, Drug Type, Route Of Administration, Drug Formulation, End-User, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 189 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5305474
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Anti-Obesity Therapeutics Market is witnessing substantial growth, evolving from USD 10.79 billion in 2024 to USD 11.69 billion in 2025, with projections pointing towards USD 17.70 billion by 2030.

A combination of scientific breakthroughs and dynamic market forces are driving this transformation, offering a comprehensive overview that supports strategic planning and provides a competitive edge.

Setting the Stage for Anti-Obesity Therapeutics Revolution

As global health challenges intensify, the fight against obesity has reached a pivotal point. New therapies, regulatory developments, and changing patient behaviors are reshaping the landscape for stakeholders in pharmaceuticals and medical devices. This report provides a detailed analysis of the scientific and market dynamics currently defining the anti-obesity sector, offering insights into potential strategic adjustments for sustained growth.

Emerging Paradigm Shifts Reshaping Treatment Approaches

Recent advancements in biologically derived agents have significantly impacted the anti-obesity field. GLP-1 receptor agonists and dual incretin therapies are redefining treatment paradigms, overshadowing traditional weight-loss methods. Innovations in endoscopic sleeve gastroplasty and gastric bypass techniques have also democratized access to minimally invasive procedures. The integration of data-driven care models through telehealth is further revolutionizing treatment, allowing real-time adjustments that enhance patient outcomes.

Unraveling the 2025 US Tariff Impact on Therapeutic Access

The revised US tariffs for 2025 present new challenges for the cost structure and supply chain of anti-obesity therapeutics. Manufacturers are rethinking sourcing strategies to counter increased import duties, while payers are reassessing formulary placements. This tariff landscape could inspire onshoring production, fostering partnerships between drug developers and domestic manufacturers. Stakeholders must navigate these changes to maintain efficient distribution and ensure continuous patient access.

Key Takeaways from This Report

  • The shift towards integrated solutions and digital engagement will be crucial for sustained leadership.
  • Investing in supply chain resilience and strategic partnerships positions companies to capitalize on diverse opportunities.
  • Staying informed on policy changes and payer expectations is vital for effective market entry strategies.

Deconstructing Market Segmentation to Reveal Growth Drivers

This in-depth analysis categorizes market drivers, shedding light on pharmaceutical innovations and procedural advancements. Newer medications like tilzepatide are gaining interest, while established treatments continue to serve supportive roles. Procedural innovations like endoscopic sleeve gastroplasty are gaining popularity over traditional methods such as gastric bypass surgery, but gastric bypass remains a crucial option for significant weight loss. The report dissects these trends across diverse drug formulations and administration routes, helping stakeholders identify key growth areas.

Regional Dynamics Driving Therapeutic Adoption Worldwide

The adoption of anti-obesity solutions varies significantly by region. The Americas benefit from robust payer systems and patient awareness, while Latin America provides fertile ground for cost-effective generic formulations. Europe, the Middle East, and Africa present a diverse landscape with varying reimbursement models, from Western Europe's value-based systems to emerging private-payer structures in the Gulf. Understanding these regional dynamics facilitates strategic market entry and competitive advantage.

Strategic Movements from Leading Therapeutic Innovators

The competitive landscape comprises established pharmaceutical companies and agile biotechs pioneering new treatments. These players form strategic alliances to enhance their offerings, combining procedural and pharmacological solutions. Partnerships with academic centers and contract research organizations ensure a steady pipeline of innovative candidates. As companies collaborate to transcend traditional therapeutic silos, strategic positioning becomes pivotal for market success.

Actionable Strategies to Capitalize on Growth Opportunities

Industry leaders should focus on cross-sector collaboration to integrate drug development and procedural advancements. Investment in digital tools and value-based contracting, coupled with engagement with payers, enhances patient outcomes and supports differentiation. Expanding manufacturing capabilities to mitigate trade barriers and proactive education initiatives also drive market adoption, anchoring competitive strategies for the future.

Rigorous Methodological Framework Underpinning the Analysis

Our comprehensive research methodology includes primary interviews with key stakeholders such as endocrinologists and bariatric surgeons, alongside secondary research from regulatory and industry databases. The report offers a robust segmentation analysis, underpinned by rigorous data triangulation and scenario planning, providing actionable insights for industry players.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Anti-Obesity Therapeutics Market, by Treatment Type
8.1. Introduction
8.2. Medications
8.2.1. Bupropion-Naltrexone
8.2.2. Liraglutide
8.2.3. Orlistat
8.2.4. Phentermine-Topiramate
8.2.5. Semaglutide
8.2.6. Tilzepatide
8.3. Treatments
8.3.1. Adjustable Gastric Banding
8.3.2. Endoscopic Sleeve Gastroplasty
8.3.3. Gastric Bypass Surgery
9. Anti-Obesity Therapeutics Market, by Drug Type
9.1. Introduction
9.2. Over-The-Counter Drugs
9.3. Prescription Drugs
10. Anti-Obesity Therapeutics Market, by Route Of Administration
10.1. Introduction
10.2. Oral Administration
10.2.1. Capsules
10.2.2. Tablets
10.3. Parenteral Administration
10.3.1. Intravenous
10.3.2. Subcutaneous
11. Anti-Obesity Therapeutics Market, by Drug Formulation
11.1. Introduction
11.2. Liquid Dosage Forms
11.3. Semi-Solid Dosage Forms
11.4. Solid Dosage Forms
12. Anti-Obesity Therapeutics Market, by End-User
12.1. Introduction
12.2. Ambulatory Surgical Centers
12.3. Hospitals
12.4. Specialty Clinics
13. Anti-Obesity Therapeutics Market, by Distribution Channel
13.1. Introduction
13.2. Hospitals & Clinics Pharmacies
13.3. Online Pharmacies
13.4. Retail Pharmacies
14. Americas Anti-Obesity Therapeutics Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Anti-Obesity Therapeutics Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Anti-Obesity Therapeutics Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Alizyme PLC
17.3.2. Amgen Inc.
17.3.3. Arena Pharmaceuticals Inc.
17.3.4. Boehringer Ingelheim International GmbH
17.3.5. Bristol-Myers Squibb Company
17.3.6. Currax Pharmaceuticals LLC
17.3.7. Eisai Co. Ltd.
17.3.8. Eli Lilly and Company
17.3.9. F. Hoffmann-La Roche Ltd
17.3.10. FlaxoSithKline plc.
17.3.11. GlaxoSmithKline PLC
17.3.12. Johnson & Johnson Services Inc.
17.3.13. Merck & Co. Inc.
17.3.14. Nalpropion Pharmaceuticals Inc.
17.3.15. Norgine B.V.
17.3.16. Novartis AG
17.3.17. Novo Nordisk A/S
17.3.18. Orexigen Therapeutics Inc.
17.3.19. Pfizer Inc.
17.3.20. Rhythm Pharmaceuticals, Inc.
17.3.21. Sanofi S.A.
17.3.22. SHIONOGI & Co., Ltd.
17.3.23. Takeda Pharmaceutical Company Limited
17.3.24. Vivus Inc.
17.3.25. Zydus Lifesciences Limited
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. ANTI-OBESITY THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. ANTI-OBESITY THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. ANTI-OBESITY THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ANTI-OBESITY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. ANTI-OBESITY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ANTI-OBESITY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY BUPROPION-NALTREXONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORLISTAT, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PHENTERMINE-TOPIRAMATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TILZEPATIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ADJUSTABLE GASTRIC BANDING, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GASTRIC BYPASS SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIQUID DOSAGE FORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SOLID DOSAGE FORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 66. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 67. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 68. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 69. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 70. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 71. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 74. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 75. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 77. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 78. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 79. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 80. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 84. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 85. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 117. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 118. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 119. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 120. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 122. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 127. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 128. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 129. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 130. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 131. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 132. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 135. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 136. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 138. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 139. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 140. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 141. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 142. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 145. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 146. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 148. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 149. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 150. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 151. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 158. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 159. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 160. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 161. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 162. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 163. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 165. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 166. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 168. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 169. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 170. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 171. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 173. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 175. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 176. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 177. UNITED ARAB EMIRATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 178. UNITED ARAB EMIRATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 179. UNITED ARAB EMIRATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 180. UNITED ARAB EMIRATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. SAUDI ARABIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 188. SAUDI ARABIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 189. SAUDI ARABIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 190. SAUDI ARABIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 192. SAUDI ARABIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. SOUTH AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 198. SOUTH AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 199. SOUTH AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 207. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 208. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 209. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 210. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 211. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 212. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 213. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 215. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 216. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. NETHERLANDS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 218. NETHERLANDS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 219. NETHERLANDS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 220. NETHERLANDS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 221. NETHERLANDS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 222. NETHERLANDS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 223. NETHERLANDS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 224. NETHERLANDS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 225. NETHERLANDS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 226. NETHERLANDS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 227. QATAR ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 228. QATAR ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 229. QATAR ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 230. QATAR ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 231. QATAR ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 232. QATAR ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 233. QATAR ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 234. QATAR ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 235. QATAR ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 236. QATAR ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 237. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 238. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 239. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 240. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 241. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 242. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 243. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 245. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 246. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 247. SWEDEN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 248. SWEDEN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 249. SWEDEN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 250. SWEDEN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 251. SWEDEN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 257. NIGERIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 258. NIGERIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 259. NIGERIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 260. NIGERIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 261. NIGERIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 262. NIGERIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 263. NIGERIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 264. NIGERIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 265. NIGERIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 266. NIGERIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 267. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 268. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 269. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 270. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 271. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 272. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 273. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 274. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 275. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 276. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 277. TURKEY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 278. TURKEY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 279. TURKEY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 280. TURKEY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 281. TURKEY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 282. TURKEY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 283. TURKEY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 284. TURKEY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 285. TURKEY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 286. TURKEY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 287. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 288. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 289. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 290. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 291. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 292. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 293. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 294. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 295. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 296. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 297. NORWAY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 298. NORWAY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 299. NORWAY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 300. NORWAY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 301. NORWAY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 302. NORWAY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 303. NORWAY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 304. NORWAY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 305. NORWAY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 306. NORWAY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 307. POLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 308. POLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 309. POLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 310. POLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 311. POLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 312. POLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 313. POLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 314. POLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 315. POLAND ANTI-OBES

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Anti-Obesity Therapeutics market report include:
  • Alizyme PLC
  • Amgen Inc.
  • Arena Pharmaceuticals Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Currax Pharmaceuticals LLC
  • Eisai Co. Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • FlaxoSithKline plc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • Nalpropion Pharmaceuticals Inc.
  • Norgine B.V.
  • Novartis AG
  • Novo Nordisk A/S
  • Orexigen Therapeutics Inc.
  • Pfizer Inc.
  • Rhythm Pharmaceuticals, Inc.
  • Sanofi S.A.
  • SHIONOGI & Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Vivus Inc.
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages189
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 11.69 Billion
Forecasted Market Value ( USD ) by 2030 $ 17.7 Billion
Compound Annual Growth Rate8.5%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Anti-obesity Prescription Drugs Market by Drug Class, Administration Route, Distribution Channel, End User - Global Forecast to 2030 - Product Image

Anti-obesity Prescription Drugs Market by Drug Class, Administration Route, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 192 Pages
  • Global
From
Obesity Treatment Market by Treatment Type, Drug Class, Route of Administration, Patient Age Group, Distribution Channel, End-User - Global Forecast to 2030 - Product Image

Obesity Treatment Market by Treatment Type, Drug Class, Route of Administration, Patient Age Group, Distribution Channel, End-User - Global Forecast to 2030

  • Report
  • 181 Pages
  • Global
From
Digital Health for Obesity - Global Strategic Business Report - Product Image

Digital Health for Obesity - Global Strategic Business Report

  • Report
  • 281 Pages
  • Global
From
Obesity: 68-Market Analysis and Sales Forecast - Product Image

Obesity: 68-Market Analysis and Sales Forecast

  • Report
  • 20 Pages
  • Global
From
Global Perspectives on Childhood Obesity - Product Image

Global Perspectives on Childhood Obesity

  • Book
  • 536 Pages
  • Global
Copyright © 2002-2025 Research and Markets. All Rights Reserved.